Patients with psoriasis and psoriatic arthritis are at a greater risk for osteopenia and osteoporosis, but the associate is the result of secondary factors, such as medication.
Patients with psoriasis and psoriatic arthritis (PsA) are at a greater risk for osteopenia and osteoporosis, but the risk is not causal. According to new research published in Annals of Rheumatic Diseases, the associate is the result of secondary factors, such as medication.
The researchers used 432,513 samples from the UK Biobank data set and a multivariable linear/logistic regression to estimate the relationship between psoriasis and PsA with bone mineral density (BMD). They also used a weighted Genetic Risk Score to estimate the effect of psoriasis/PsA on estimated BMD.
The authors categorized potential confounders in 3 ways: model0 included age, height, weight, smoking, and drinking; model1 included model0 plus regular physical activity; and model2 included model1 plus medication treatments.
A total of 4904 patients with psoriasis and 847 patients with PsA were included in the analysis. The study also included control participants.
While the data suggest an association between PsA and lower estimated BMD in model0 and model1 compared with controls, the association disappeared with treatment with methotrexate or ciclosporin, suggesting the association was secondary. Patients with psoriasis showed no difference in association of estimated BMD compared with controls.
The authors also found that, according to the weighted Genetic Risk Score, the association between PsA and BMD was not genetically determined.
The researchers concluded that patients with PsA “should be screened for osteopenia and osteoporosis and proper management should be provided to reduce the fracture risk, especially for those who received treatment with methotrexate or ciclosporin.”
Reference
Xia J, Xie SY, Liu KQ, et al. Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study. Ann Rheum Dis. Published online July 31, 2020. doi:10.1136/annrheumdis-2020-217892
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More